Efg Asset Management (Americas) Corp. Neurocrine Biosciences Inc Transaction History

Efg Asset Management (Americas) Corp.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$130.4 - $143.74 $134,703 - $148,483	-1,033 Reduced 36.8%	1,774 $244,000
Q4 2023 Feb 01, 2024	SELL	$106.07 - $132.76 $43,488 - $54,431	-410 Reduced 12.74%	2,807 $369,000
Q3 2023 Nov 09, 2023	BUY	$94.02 - $117.1 $7,239 - $9,016	77 Added 2.45%	3,217 $361,000
Q2 2023 Aug 29, 2023	BUY	$89.53 - $104.87 $41,989 - $49,184	469 Added 17.56%	3,140 $296,000
Q1 2023 May 04, 2023	BUY	$94.11 - $123.02 $56,748 - $74,181	603 Added 29.16%	2,671 $270,000
Q4 2022 Feb 09, 2023	SELL	$106.72 - $127.06 $13,233 - $15,755	-124 Reduced 5.66%	2,068 $247,000
Q2 2022 Jul 13, 2022	SELL	$75.79 - $100.07 $9,852 - $13,009	-130 Reduced 5.6%	2,192 $214,000
Q1 2022 May 05, 2022	BUY	$72.45 - $94.81 $168,228 - $220,148	2,322 New	2,322 $218,000
Q2 2020 Jul 30, 2020	SELL	$85.09 - $130.36 $1.72 Million - $2.64 Million	-20,240 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$75.11 - $113.76 $17,200 - $26,051	229 Added 1.14%	20,240 $1.75 Million
Q4 2019 Jan 28, 2020	SELL	$86.8 - $118.57 $385,392 - $526,450	-4,440 Reduced 18.16%	20,011 $2.15 Million
Q3 2019 Nov 05, 2019	BUY	$83.82 - $101.5 $2.05 Million - $2.48 Million	24,451 New	24,451 $2.2 Million
Q1 2019 Apr 05, 2019	SELL	$69.31 - $91.53 $1.54 Million - $2.03 Million	-22,184 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$68.32 - $124.36 $161,440 - $293,862	2,363 Added 11.92%	22,184 $1.58 Million
Q3 2018 Oct 09, 2018	BUY	$98.88 - $125.85 $1.96 Million - $2.49 Million	19,821 New	19,821 $2.44 Million

641

95.3M

661K

227K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.